According to the tumor staging system and the evaluation of the tumor size, lymph nodes involvement, and distant metastasis, it became clear that patients with HER20 had more basal-like behavior and a more aggressive type of tumor; whereas patients with HER2+ had a less aggressive tumor and mostly were not basal-like tumor. This evidence concerns the gene ERBB2 and neoplasm.